세계 암 줄기세포 치료 시장 예측(-2030년) : 암 유형별, 치료 유형별, 최종 사용자별, 지역별 분석

According to Stratistics MRC, the Global Cancer Stem Cells Therapy Market is accounted for $4.9 billion in 2023 and is expected to reach $11.1 billion by 2030 growing at a CAGR of 12.2% during the forecast period. The Cancer Stem Cells Therapy involves the development and implementation of therapeutic strategies specifically targeting cancer stem cells (CSCs), a subpopulation of cells within tumors believed to possess self-renewal and differentiation capabilities. These cells are implicated in tumor initiation, progression, and treatment resistance. Cancer stem cell therapy aims to eradicate or inhibit the growth of these cells, thereby addressing the root cause of cancer and preventing relapse.

According to World Health Organization (WHO), cancer was the leading cause of death worldwide, accounting for nearly 10 million deaths in 2020.

Market Dynamics:

Driver:

Growing emphasis on personalized medicine

Due to the intricate molecular and genetic factors influencing cancer advances, there is a paradigm shift towards tailoring treatments based on individual patient characteristics. Cancer stem cells, with their distinct molecular profiles, play a pivotal role in tumor development and recurrence. The emphasis on personalized medicine aligns seamlessly with the objective of targeting these specific cellular components, allowing for more precise and effective therapeutic interventions. Additionally, by customizing cancer stem cell therapies to the unique genetic makeup of each patient, the potential for improved treatment outcomes and reduced side effects becomes apparent.

Restraint:

High development costs

The intricate nature of cancer stem cell research, coupled with the stringent regulatory requirements for clinical trials and drug approvals, contributes to substantial financial investments. The extensive research needed to unravel the complexities of cancer stem cells, conduct preclinical studies, and progress through rigorous clinical trial phases amplifies development expenses. Moreover, the uncertainty associated with the success and commercial viability of these therapies adds to the financial risk. Pharmaceutical companies and research institutions face the challenge of balancing the imperative to innovate with the financial burden of bringing novel cancer stem cell therapies to market.

Opportunity:

Increasing investment in oncology research

As the understanding of cancer biology evolves, there is a growing recognition of the pivotal role played by cancer stem cells in tumor initiation and progression. This realization has prompted a surge in research funding, both from public and private sectors, dedicated to unraveling the complexities of cancer stem cells and developing targeted therapies. The heightened focus on identifying innovative treatment modalities and advancing scientific knowledge in oncology creates a conducive environment for the emergence of novel cancer stem cell therapies.

Threat:

Ethical and regulatory concerns

The intricate nature of stem cell research, including the use of embryonic stem cells, raises ethical considerations surrounding the source and derivation of cells for therapy. This has prompted ongoing debates and, at times, regulatory restrictions, creating hurdles in the development and acceptance of certain stem cell-based treatments. Additionally, stringent regulatory frameworks governing clinical trials and therapeutic approvals contribute to the challenges faced by researchers and developers in bringing cancer stem cell therapies to market.

COVID-19 Impact:

While the crisis emphasized the urgent need for innovative therapies, including those targeting cancer stem cells, disruptions in research activities, clinical trials, and healthcare services have impeded the market's trajectory. The redirection of resources toward pandemic-related efforts, delays in clinical trial timelines, and challenges in patient recruitment have slowed down the pace of cancer stem cell therapy development. Additionally, economic uncertainties and shifts in healthcare priorities have influenced funding availability and investment patterns in the sector.

The breast cancer stem cells therapy segment is expected to be the largest during the forecast period

Breast Cancer Stem Cells Therapy segment dominated the largest share of the market over the forecast period due to its targeted approach in treating breast cancer at its roots. The therapeutic focus on these specific cells allows for more effective and sustained treatment outcomes, reducing the likelihood of cancer relapse. This precision in targeting cancer stem cells enhances the overall efficacy of therapies, contributing to increased adoption and demand in the market. Additionally, ongoing research and advancements in understanding the molecular mechanisms of breast cancer stem cells further fuel the development of innovative therapies, attracting investments and driving market expansion.

The gene therapy segment is expected to have the highest CAGR during the forecast period

Gene Therapy segment is estimated to witness lucrative growth over the projection period due to the advanced genetic techniques to specifically target and modify cancer stem cells. Gene therapy enables the introduction of therapeutic genes or the manipulation of existing ones to disrupt the signaling pathways crucial for the survival and proliferation of cancer stem cells. Furthermore, this innovative approach not only enhances the precision of cancer treatment but also minimizes damage to normal cells, reducing side effects.

Region with largest share:

Asia Pacific region commanded the largest market share over the extrapolated period due to a surge in cancer incidence, with breast, lung, and colorectal cancers being particularly prevalent. This high disease burden has spurred increased investments in advanced medical research and treatment modalities, creating a conducive environment for the expansion of cancer stem cell therapies. Moreover, the Asia Pacific region has experienced rapid technological advancements and innovation in the healthcare sector, fostering the development of cutting-edge therapies, including those targeting cancer stem cells.

Region with highest CAGR:

Asia Pacific region is projected to grow at a rapid pace owing to a strong focus on research and development, coupled with a burgeoning biotechnology and pharmaceutical industry, has paved the way for the discovery of novel therapeutic approaches that specifically target cancer stem cells, enhancing treatment efficacy. As a result, there is a notable increase in the adoption of cancer stem cell therapies, driven by the demand for more precise and tailored treatment options. Additionally, governments and regulatory bodies in the region are also actively supporting advancements in healthcare infrastructure, research initiatives, and clinical trials, creating an environment conducive to the rapid integration of novel therapies into mainstream cancer care.

Key players in the market:

Some of the key players in Cancer Stem Cells Therapy market include AbbVie Inc., AdnaGen AG, Astellas Pharma Inc., Bristol Myers Squibb, Cancer Stem Cells Co., Ltd, Gamida Cells, Glycosyn LLC, Johnson & Johnson, Merck & Co., Inc., Novadip Biosciences, Novartis AG, OncoMed Pharmaceuticals, Pfizer Inc, Roche Holdings AG, Stemline Therapeutics, Inc. and Thermo Fisher Scientific, Inc.

Key Developments:

In December 2023, Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH. Significant unmet need remains in PNH, a chronic and rare blood disorder; despite anti-C5 therapy, a large proportion of patients can remain anemic and dependent on blood transfusions

In July 2023, US FDA approves expanded indication for Novartis Leqvio® (inclisiran) to include treatment of adults with high LDL-C and who are at increased risk of heart disease. Leqvio can now be used earlier in LDL-C treatment as an adjunct to diet and statin therapy for patients who have not had a cardiovascular event but are at an increased risk of heart disease

Cancer Types Covered:

• Brain Cancer Stem Cells Therapy
• Breast Cancer Stem Cells Therapy
• Colorectal Cancer Stem Cells Therapy
• Lung Cancer Stem Cells Therapy
• Prostate Cancer Stem Cells Therapy
• Other Cancer Types

Therapeutic Types Covered:

• Chemotherapy
• Immunotherapy
• Radiation Therapy
• Stem Cell Transplantation
• Targeted Therapy
• Differentiation Therapy
• Gene Therapy
• Nanoparticle-Based Therapies
• Combination Therapies
• Other Therapeutic Types

End Users Covered:

• Cancer Research Institutes
• Hospitals
• Specialty Clinics
• Academic Medical Centers
• Healthcare Professionals
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Cancer Stem Cells Therapy Market, By Cancer Type

• 5.1 Introduction
• 5.2 Brain Cancer Stem Cells Therapy
• 5.3 Breast Cancer Stem Cells Therapy
• 5.4 Colorectal Cancer Stem Cells Therapy
• 5.5 Lung Cancer Stem Cells Therapy
• 5.6 Prostate Cancer Stem Cells Therapy
• 5.7 Other Cancer Types

6 Global Cancer Stem Cells Therapy Market, By Therapeutic Type

• 6.1 Introduction
• 6.2 Chemotherapy
• 6.3 Immunotherapy
• 6.4 Radiation Therapy
• 6.5 Stem Cell Transplantation
• 6.6 Targeted Therapy
• 6.7 Differentiation Therapy
• 6.8 Gene Therapy
• 6.9 Nanoparticle-Based Therapies
• 6.10 Combination Therapies
• 6.11 Other Therapeutic Types

7 Global Cancer Stem Cells Therapy Market, By End User

• 7.1 Introduction
• 7.2 Cancer Research Institutes
• 7.3 Hospitals
• 7.4 Specialty Clinics
• 7.5 Academic Medical Centers
• 7.6 Healthcare Professionals
  • 7.6.1 Surgeons
  • 7.6.2 Radiation Oncologists
  • 7.6.3 Hematologists
• 7.7 Other End Users

8 Global Cancer Stem Cells Therapy Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 AbbVie Inc.
• 10.2 AdnaGen AG
• 10.3 Astellas Pharma Inc.
• 10.4 Bristol Myers Squibb
• 10.5 Cancer Stem Cells Co., Ltd
• 10.6 Gamida Cells
• 10.7 Glycosyn LLC
• 10.8 Johnson & Johnson
• 10.9 Merck & Co., Inc.
• 10.10 Novadip Biosciences
• 10.11 Novartis AG
• 10.12 OncoMed Pharmaceuticals
• 10.13 Pfizer Inc
• 10.14 Roche Holdings AG
• 10.15 Stemline Therapeutics, Inc.
• 10.16 Thermo Fisher Scientific, Inc